Recent long-term allogeneic bone marrow transplantation (BMT) results.18,;26,;28 –30
N . | Survival . | Age . | Source . |
---|---|---|---|
Abbreviations: TAI, thoracoabdominal irradiation; Cy, cyclophosphamide; ATG, antithymocyte globulin; GVHD, graft-versus-host disease; CsA, cyclosporine; MTX, methotrexate | |||
133 | 59% at 16 y for TAI/Cy 95% at 4.4 y for ATG/Cy | 55% < 20 y | France |
211 | 89% at 20 y without GVHD 69% at 20 y with GVHD | 18 y | FHCRC |
915 | Actuarial survival 77% for patients 68% for patients 17–40 y 54% for patients > 40 y | ≤ 16 y | EBMT |
61 | At 6 y 79% | 14–40 y | Korea |
71 | 94% at 8 y with CsA/MTX 78% at 7 y with CsA | 20 y | GITMO |
1699 | 5 y survival: 75% for patients ≤ 20 y 68% for patients 20–40 y 35% for patients > 40 y | IBMTR |
N . | Survival . | Age . | Source . |
---|---|---|---|
Abbreviations: TAI, thoracoabdominal irradiation; Cy, cyclophosphamide; ATG, antithymocyte globulin; GVHD, graft-versus-host disease; CsA, cyclosporine; MTX, methotrexate | |||
133 | 59% at 16 y for TAI/Cy 95% at 4.4 y for ATG/Cy | 55% < 20 y | France |
211 | 89% at 20 y without GVHD 69% at 20 y with GVHD | 18 y | FHCRC |
915 | Actuarial survival 77% for patients 68% for patients 17–40 y 54% for patients > 40 y | ≤ 16 y | EBMT |
61 | At 6 y 79% | 14–40 y | Korea |
71 | 94% at 8 y with CsA/MTX 78% at 7 y with CsA | 20 y | GITMO |
1699 | 5 y survival: 75% for patients ≤ 20 y 68% for patients 20–40 y 35% for patients > 40 y | IBMTR |